JMJoëlle Micallef

Joëlle Micallef

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joëlle Micallef has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • French Specific Surveillance System for Drug Abuse

    by Elisabeth Frauger, Christophe Moracchini, Françoise Albertini, Xavier Thirion, Joëlle Micallef

    It is important to assess drug abuse liability in real life by post-marketing surveillance system. In France, to obtain information on drug abuse liability, the Centers for Evaluation and Information on Pharmacodependence (CEIP) network was created in 1990 with the following aims: detection, prevention, evaluation, and information on drug abuse liability. Its specific work is based on a global, scientific assessment involving preclinical data, clinical studies, and post-marketing surveillance. This network has developed several pharmaco-epidemiological approaches to improve knowledge of drug use in real-life. The aim of this article was to describe a French post-marketing surveillance called OPPIDUM (Observation des Produits Psychotropes Illicites ou Détournés de leur Utilisation Médicamenteuse, Observation of Illegal Drugs and Misuse of Psychotropic Medications). OPPIDUM is an annual cross-sectional survey that collects anonymous information on abuse and dependence observed in patients recruited by specialized care centers dedicated to drug dependence. For each patient included sociodemographic data and psychoactive substance consumptions during the previous week were collected. From 1990 to 2010, a total of 50,734 patients were included with descriptions of 102,631 psychoactive substances. This OPPIDUM data has outlined emergent behaviors, such as use of high dosage buprenorphine by intravenous administration. It has contributed to characterize patients under opiate maintenance treatments and to assess abuse liability of emergent drugs as clonazepam. This pharmacoepidemiologic tool has also detected the decrease of flunitrazepam abuse following implementation of regulatory measures. OPPIDUM’s experience clearly demonstrates that collection of valid and useful data on drug abuse is possible. This post-marketing surveillance system offers important and useful information for physicians and health authorities.


    • 1 January 2013
      • Vol. 16  (1) , 89-100

    Doctor shopping reveals geographical variations in opioid abuse.

    by Sandra Nordmann, Vincent Pradel, Maryse Lapeyre-Mestre, Elisabeth Frauger, Vanessa Pauly, Xavier Thirion, Michel Mallaret, Emilie Jouanjus, Joëlle Micallef

    Prescription opioid abuse is not homogeneous due to varying patterns of use and different geographic preferences. Because doctor shopping is one of the main sources of diversion, it has previously been used to estimate drug abuse. The aim of this study was to describe and compare opioid abuse in 2008 using doctor shopping to estimate abuse in 3 French regions. Data for this study came from the General Health Insurance (GHI) reimbursement database, which covers 77% of the French population. All individuals living in Provence-Alpes-Cote d'Azur-Corse (PACA), Rhone-Alpes (RA), or Midi-Pyrenees (MP) that received at least one reimbursement for oral opioids from the GHI in 2008 were included. Oral opioids under study were opioids for mild to moderate pain (dextropropoxyphene, codeine, tramadol, dihydrocodeine), opoids for moderately severe to severe pain (oral morphine, oxycodone, buprenorphine painkiller, hydromorphone), and opioid maintenance treatments (buprenorphine maintenance, methadone). For a given opioid, the Doctor Shopping Quantity (DSQ) is the quantity obtained by overlapping prescriptions from several prescribers. It is used to estimate the magnitude of abuse. The Doctor Shopping Indicator (DSI) is the DSQ divided by the total dispensed quantity. It is used to estimate the abuse corrected for use. The total DSQ for opioids in PACA (213.3 DDD/1,000 inhabitants) was twofold superior to that in RA (115.1 DDD/1,000) and in MP (106.2 DDD/1,000). The DSQ of opioids for mild to moderate pain was 75.5DDD/1000 (DSI=1.1%), 19.7DDD/1,000 (DSI=5.0%) for opioids for moderately severe to severe pain, and 55.3DDD/1,000 (DSI=6.2%) for opioid maintenance treatments. Emergent signals of abuse have been observed at a regional level for oxycodone in MP and dihydrocodeine in RA and MP. The main limitation of this study is that the GHI reimbursement database provides information about dispensed and reimbursed prescription drugs, and not necessarily the actual quantity used. These results confirm important variations in the 3 French regions despite them being geographically close. Besides, they highlight different rates of opioid abuse between opioids for mild to moderate pain, opioids for moderately severe to severe pain, and opioid maintenance treatments, as well as differences within these groups.


  • Which psychoactive prescription drugs are illegally obtained and through which ways of acquisition? About OPPIDUM survey

    by Elisabeth Frauger, Sandra Nordmann, Veronica Orleans, Vincent Pradel, Vanessa Pauly, Xavier Thirion, Joëlle Micallef, Réseau Des Ceips

    The objective of the study was to determine which psychoactive prescription drugs are illegally obtained and through which ways of acquisition. OPPIDUM is an annual national study. It is based on specialized care centers that included subjects presenting a drug dependency or under opiate maintenance treatment. All their psychoactive substances consumed are reported. This work focuses on the different ways of acquisition specially the illegal ways of acquisition (bought on the street, forged prescription, stolen, given, internet). For each medication illegally obtained, a ratio has been calculated (number of illegal acquisitions divided by the number of described acquisitions). In 2008, 5542 subjects have been included and have described the consumption of 11 027 substances including 63.8% of prescription drugs. Among them, 11% were illegally obtained. The different illegal acquisition ways were ‘street market’ (77.6%), ‘gift’ (16.6%), ‘theft’ (2.3%), ‘forged prescription’ (2.3%), and ‘internet’ (0.7%). The third first drugs illegally obtained were high dosage buprenorphine, methadone, and clonazepam. Some prescription drugs, less consumed, have an important ratio of illegal acquisition like ketamine, flunitrazepam, morphine, trihexyphenidyl, or methylphenidate. This study confirms that theft, forged prescription and internet are few used and permits to highlight diversion of prescription drugs. It is important to inform healthcare professionals on the different prescription drugs that are illegally obtained.


  • Assessment of abuse of tianeptine from a reimbursement database using ‘doctor‐shopping’ as an indicator

    by Frank Rouby, Vincent Pradel, Elisabeth Frauger, Vanessa Pauly, François Natali, Patrick Reggio, Xavier Thirion, Joëlle Micallef

    Doctor‐shopping is a patient behaviour characterized by simultaneous consultations of several physicians during the same period. Some case reports have described an abuse of tianeptine, an atypical antidepressant. Our objective was to assess the extent of abuse of this drug with a method quantifying doctor‐shopping in comparison with other antidepressants and benzodiazepines (BZD). All dispensations of antidepressants and BZD during the year 2005 in a French area of 4.5 million inhabitants were extracted from a reimbursement database. For each patient, two quantities were computed: quantity dispensed and obtained by doctor‐shopping. Tianeptine and other drugs were compared using their doctor‐shopping indicator (DSI), defined as the percentage of drug obtained by doctor‐shopping among dispensed quantity; 410 525 patients received at least one antidepressant dispensation during the year 2005. Tianeptine was the sixth most dispensed antidepressant. The DSI of tianeptine was 2.0%, ranking it first among antidepressant (the second being mianserine with a DSI of 1%). Flunitrazepam has the highest DSI (30.2%), the DSI of the five following BZD (clonazepam, zolpidem, oxazepam, diazepam, bromazepam) range from 3.0% to 2.0%. Tianeptine is associated with higher DSI, compared with other antidepressants, suggesting that it may be subject to abuse in the population. Moreover, its DSI as a measure of diversion is similar to the DSI of diazepam or bromazepam.


  • Which indicators can public health authorities use to monitor prescription drug abuse and evaluate the impact of regulatory measures? Controlling High Dosage Buprenorphine abuse

    by Vanessa Pauly, Elisabeth Frauger, Vincent Pradel, Franck Rouby, Julie Berbis, François Natali, Patrick Reggio, Hervé Coudert, Joelle Micallef, Xavier Thirion


  • Assessment of doctor‐shopping for high dosage buprenorphine maintenance treatment in a French region: development of a new method for prescription database

    by Vincent Pradel, Xavier Thirion, Eléonore Ronfle, Alain Masut, Joëlle Micallef, Bernard Bégaud

    Purpose To assess the extent of doctor-shopping for buprenorphine maintenance therapy in a French region with a specific indicator. Methods Use of a quasi-exhaustive prescription database in a French region (information system of the French General Health Insurance Scheme). Extraction of all buprenorphine prescriptions between September 1999 and December 2000. Definition and calculation of three quantities for each patient: delivered, prescribed and doctor-shopping quantity. The calculation of these three quantities is done by an automated and reproducible method determining the overlaps in prescription periods of different physicians for a given patient. Calculation of the corresponding daily dose was done for each quantity. Results A total of 64 326 prescriptions of buprenorphine by 1313 physicians to 3259 patients were extracted. Quantities and doses were calculated for 2587 patients. The total doctor-shopping quantity represented 18.6% of the delivered quantity. Doctor-shopping involved a minority of patients and was highly concentrated: 87 patients with doctor-shopping doses superior to 16 mg/day were responsible for 45.4% of the total doctor-shopping quantity. Conclusions Doctor-shopping appears to be an important problem for buprenorphine maintenance treatment in France but may be resolved by regulatory interventions. The use of adequate indicators on prescription databases may help to limit the effects of such interventions on legitimate care. The method presented here may be used with slight adaptations for other medications to assess their abuse potential. Copyright © 2003 John Wiley & Sons, Ltd.


    • 1 June 2003
      • p. S7-14

    [High-dose buprenorphine prescription in southern France from 1999 to 2001].

    by Julien Mancini, Xavier Thirion, Alain Masut, Eléonore Ronflé, Christine Coudert, Vincent Pradel, Elisabeth Frauger, Joëlle Micallef

    Several reports have focused on prescription of high-dose buprenorphine using data electronically transmitted to the French health reimbursement system. This study deals with high-dose buprenorphine prescriptions in the Bouches-du-Rhone region between 1999 and 2001. We determined the number of maintained patients followed by practitioners (either short- or long-term care), the doses administered, and the associated prescription of psychotropic treatments. The number of general practitioners involved in 84% of the prescriptions of high-dose buprenorphine grew with a high turnover (20%). More than 25% of the general practitioners in the region prescribed this drug, but only 38% of them were involved in long-term follow-up of more than one maintained patient. The number of maintained patients and the mean daily treatment dose delivered (13.4 mg/d during 2001) increased. The associated prescriptions of benzodiazepines concerned 47% of the patients during 2001 (on the rise), but the associated prescription of flunitrazepam tended to decrease (29% of the subjects during 2001 versus 32% during 2000). This study shows a tendency for deviant behaviors to increase, constituting a public health concern.